

ASX Release

9th April 2014

Key Licence Provided by NewSouth Innovations

PharmAust Limited ("PharmAust") (ASX: PAA & PAAO) is pleased to announce that further to its announcement on 17 February 2014 that it had made an important discovery in the area of cancer therapy based on a biochemical pathway for killing cancer cells, it has now received an exclusive royalty-free worldwide licence from NewSouth Innovations (NSi), the commercialisation arm of the University of New South Wales, in respect of NSi's joint ownership of that patent filing. NSi was a joint applicant to this filing along with PharmAust.

The discovery relates to the significant enhancement of the anti-cancer activity of certain well-established mainstream approved cancer drugs without simultaneously enhancing the associated side-effect profile occurring through the killing of normal-dividing cells; a factor that often limits the therapeutic value and utility of chemotherapy.

PharmAust is proceeding to undertake further work on this discovery as part of its development of its key anti-cancer product, PPL-1.

PharmAust acknowledges and thanks NSi for the licence and their continued support of the work emanating from St George Hospital, Sydney.

For further details please contact:

**Mr Robert Bishop
Executive Director
PharmAust Limited
0417 445 180**

www.pharmaust.com